Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.
Core Innovation
The document describes a nucleic acid encoding an anti-BCMA chimeric antigen receptor with an anti-BCMA single-chain variable fragment, a transmembrane domain, a co-stimulatory domain, and an activating domain. The scFv contains specified heavy- and light-chain variable regions. The document also describes a method of making an anti-BCMA CAR-T cell by introducing the encoding nucleic acid into a T cell.
The disclosed construct includes a CD8 leader and hinge, a CD28 transmembrane domain and co-stimulatory domain, and a CD3ζ activating domain. The document reports selective killing of BCMA-positive cells and elevated IFN-γ responses against BCMA-positive targets. It also reports reduced RPMI8226 xenograft tumor growth without decreased mouse body weight.
The background section is not included in the provided partial content, so the problem being solved is not explicitly described in the supplied text. The disclosed experiments concern activity against BCMA-positive targets and an RPMI8226 multiple myeloma xenograft. The provided content does not state a broader problem or identify a comparison with existing treatments.
Claims Coverage
The two independent claims cover a nucleic acid encoding an anti-BCMA CAR and a method of making an anti-BCMA CAR-T cell using that nucleic acid. They contain two inventive features.
Nucleic acid encoding an anti-BCMA CAR
Independent claim 1 covers a nucleic acid encoding an anti-BCMA CAR with an scFv comprising specified heavy- and light-chain variable-region amino acid sequences, together with a transmembrane domain, a co-stimulatory domain, and an activating domain.
Method of making an anti-BCMA CAR-T cell
Independent claim 8 covers introducing into a T cell a nucleic acid encoding an anti-BCMA CAR. The CAR comprises an scFv with the specified heavy- and light-chain variable regions, a transmembrane domain, a co-stimulatory domain, and an activating domain.
The independent claims cover the encoding nucleic acid and its use to make an anti-BCMA CAR-T cell. Both specify the anti-BCMA scFv and the CAR’s transmembrane, co-stimulatory, and activating domains.
Stated Advantages
The document reports selective killing of BCMA-positive cells.
The document reports elevated IFN-γ responses against BCMA-positive targets.
The document reports reduced RPMI8226 xenograft tumor growth without decreased mouse body weight.
Documented Applications
Making anti-BCMA CAR-T cells by introducing a nucleic acid encoding the CAR into T cells.
The document describes testing CAR-T activity against BCMA-positive cells, including CHO-BCMA cells and RPMI8226 multiple myeloma cells.
The document describes evaluation of the CAR-T cells in an NSG mouse xenograft of RPMI8226 cells.
Interested in licensing this patent?